I missed that the decrease in mortality and respir

I missed that the decrease in mortality and respiratory failure wasn’t statistically significant at the 75% interim analysis. That leaves the window open to be statically significant at the final readout, but it seems less likely. Merck will have to do a larger trial to get those endpoints to reach statistical significance. The 60% better chance to achieve clinical recovery in S/C patients was statistically significant. Merck could possibly file an EUA with the endpoint, which will be further defined when the data is published. Looks like this drug may be behind leronlimab in the trial process if the increase in clinical recovery is not sufficient enough for approval. But given the recent EUAs, I’m sure Merck will file.